➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Moodys
Dow
Medtronic
McKesson

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,174,982

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,174,982
Title:Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Inventor(s): Bruncko; Milan (Green Oaks, IL), Ding; Hong (Gurnee, IL), Doherty; George A. (Libertyville, IL), Elmore; Steven W. (Northbrook, IL), Hasvold; Lisa A. (Grayslake, IL), Hexamer; Laura (Grayslake, IL), Kunzer; Aaron R. (Schaumburg, IL), Song; Xiaohong (Grayslake, IL), Souers; Andrew J. (Evanston, IL), Sullivan; Gerard M. (Lake Villa, IL), Tao; Zhi-Fu (Gurnee, IL), Wang; Gary T. (Libertyville, IL), Wang; Le (Vernon Hills, IL), Wang; Xilu (Grayslake, IL), Wendt; Michael D. (Vernon Hills, IL), Mantei; Robert A. (Franklin, WI), Hansen; Todd M. (Grayslake, IL)
Assignee: ABBVIE INC. (North Chicago, IL) GENENTECH, INC. (South San Francisco, CA) THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (Parkville, AU)
Application Number:14/038,304
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,174,982
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,174,982

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No   Start Trial   Start Trial TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No   Start Trial   Start Trial TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No   Start Trial   Start Trial TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
Dow
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.